Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of dose intensification in non-metastatic Ewing's sarcoma
2008-008361-35Phase 3Completed
- Sponsor
- Istituto Ortopedico Rizzoli
- Start
- Mar 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vincristine, actinomycin D, doxorubicin, cyclophosphamide, ifosfamide and 3 more in Ewing sarcoma of bone and primitive neuroectodermal tumor of bone (pPNET) (2 arms), sponsored by Istituto Ortopedico Rizzoli. Primary endpoint: Non-inferiority of survival. Started Mar 2009; status: completed.
02
Drugs
vincristineactinomycin Ddoxorubicincyclophosphamideifosfamide
03
Conditions
Ewing sarcoma of boneprimitive neuroectodermal tumor of bone (pPNET)
Beyond the preview
Go deeper on 2008-008361-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008361-35.